Ann Oncol

1. XU B, Jeong H, Sun T, Sohn J, et al
   OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast Cancer.
   Ann Oncol. 2026 Mar 13:S0923-7534(26)00100-6. doi: 10.1016/j.annonc.2026.
   

   >> Share

   
   

   
   Ann Surg Oncol

2. DIMAANO K, Castillo O Jr, Moazzez A, Ozao-Choy J, et al
   ASO Visual Abstract: Examining the Representation of Minority Race and Ethnicity Groups in Breast Cancer Clinical Trials in the United States Published 2012-2022.
   Ann Surg Oncol. 2026 Mar 17. doi: 10.1245/s10434-026-19368.
   

   >> Share

   
   
3. SCHRANK Z, Landrum K, Agala CB, Gallagher KK, et al
   Impact of Age on Use of Neoadjuvant Chemoimmunotherapy and Outcomes for Patients with Triple-Negative Breast Cancer.
   Ann Surg Oncol. 2026 Mar 14. doi: 10.1245/s10434-026-19198.
   

   >> Share

   
   
4. SHAH A, Love JA, Butler M, Butler LN, et al
   Integrating Generative AI into Nomograms for Breast Cancer Nodal Risk Predictions.
   Ann Surg Oncol. 2026 Mar 13. doi: 10.1245/s10434-026-19482.
   

   >> Share

   
   

   
   BMC Cancer

5. LIU S, Li Y, Shen Y, Mao Q, et al
   Redefining M1: a novel three-tiered classification stratifies prognosis in metastatic breast cancer.
   BMC Cancer. 2026 Mar 19. doi: 10.1186/s12885-026-15861.
   

   >> Share

   
   
6. AMUJI DN, Iweala EEJ
   Association of MET gene polymorphisms with breast cancer risk in Nigerian patients: a case-control study.
   BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15844.
   

   >> Share

   
   
7. ARRARAS JI, Illarramendi JJ, Manterola A, Giesinger JM, et al
   The EORTC updated breast cancer quality of life questionnaire EORTC QLQ-BR42: A psychometric study with Spanish patients.
   BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15831.
   

   >> Share

   
   
8. GUO HL, Xie HY, Jiang CL, Weng CF, et al
   Surface-guided radiation therapy combined with real-time position management-guided deep inspiratory breath-hold radiotherapy for left breast cancer.
   BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15846.
   

   >> Share

   
   
9. FATIREGUN OA, Sutradhar R, Podolsky S, Eisen A, et al
   Mammographic screening and time to breast cancer diagnosis among immigrants and long-term residents in Ontario.
   BMC Cancer. 2026 Mar 19. doi: 10.1186/s12885-026-15693.
   

   >> Share

   
   
10. ATTAH DA, Nsaful J, Sefogah PE
    Coping with breast cancer in Ghana: a qualitative study of women's lived experiences following breast cancer diagnosis.
    BMC Cancer. 2026 Mar 18. doi: 10.1186/s12885-026-15857.
    

    >> Share

    
    
11. GUPTA R, Gopalsamy IK, Nadukkandy AS, Singh A, et al
    GCNT3 and ST3GAL1 expression correlates with HER2 status and MUC1/beta-catenin/Cyclin D1 axis in breast cancer.
    BMC Cancer. 2026 Mar 19. doi: 10.1186/s12885-026-15821.
    

    >> Share

    
    
12. MAVILI HS, Atmis O, Pehlivan FS, Ekinci F, et al
    Stromal hypoxia and autophagy signatures as indicators of pathologic response in triple-negative breast cancer.
    BMC Cancer. 2026 Mar 13. doi: 10.1186/s12885-026-15860.
    

    >> Share

    
    
13. OZCAN D, Nielsen PS, Alsner J, Nielsen MH, et al
    Associations between tumor immune response and prognosis in node-negative breast cancer patients in the randomized DBCG HYPO trial.
    BMC Cancer. 2026 Mar 13. doi: 10.1186/s12885-026-15859.
    

    >> Share

    
    

    
    BMJ

14. MA F, Yan M, Li W, Ouyang Q, et al
    Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.
    BMJ. 2026;392:e087259.
    

    >> Share

    
    

    
    Br J Cancer

15. AZAM S, An A, Kensler KH, Weiner MG, et al
    The impact of social drivers of health on delayed time to breast cancer surgery.
    Br J Cancer. 2026 Mar 14. doi: 10.1038/s41416-026-03380.
    

    >> Share

    
    

    
    Breast Cancer

16. KUSUHARA S, Kogawa T, Shimokawa M, Funasaka C, et al
    Expression of HER2, HER3, and TROP2 in primary tumors and brain metastases of breast cancer.
    Breast Cancer. 2026 Mar 13. doi: 10.1007/s12282-026-01841.
    

    >> Share

    
    
17. SOLDANI M, Privitera D, Caradonna C, Papagni G, et al
    Quality of life in women with breast cancer undergoing chemotherapy: a comparative cross-sectional study of CICC ports and PICC-ports.
    Breast Cancer. 2026 Mar 18. doi: 10.1007/s12282-026-01843.
    

    >> Share

    
    

    
    Breast Cancer (Auckl)

18. BELLAH SF, Hossen MA, Billah SS, Durojaye OA, et al
    Zeste White 10 May Serve as a Prognostic Biomarker and Therapeutic Target for Human Breast Cancer.
    Breast Cancer (Auckl). 2026;20:11782234261428784.
    

    >> Share

    
    

    
    Breast Cancer (Dove Med Press)

19. LI Y, Wang W
    Ovarian Escape in Hormone Receptor-Positive Breast Cancer: Mechanisms, Risk Factors, Clinical Consequences, and Management Strategies.
    Breast Cancer (Dove Med Press). 2026;18:586408.
    

    >> Share

    
    
20. KONG J, Tian R, Li S, Zang H, et al
    SLAMF8 Promotes M2 Polarization of Macrophages and Enhances Breast Cancer Proliferation.
    Breast Cancer (Dove Med Press). 2026;18:560682.
    

    >> Share

    
    
21. FENG G, Zhong M, Xie D, Yuan X, et al
    The Correlation Between CD8+ Tumor-Infiltrating Lymphocytes and the Efficacy of Neoadjuvant Therapy in Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:533799.
    

    >> Share

    
    
22. CHENG Y, Kong J, Liu X, Li S, et al
    Recent Advances and Emerging Directions in Machine Learning-Based Breast Cancer Drug Discovery: A Comprehensive Review.
    Breast Cancer (Dove Med Press). 2026;18:586786.
    

    >> Share

    
    
23. KANG S, Li Z, Lv C, Zhang F, et al
    Development of a Prognostic Stratification Model and Identification of BDH1 as an Oncoprotein in Breast Cancer Based on Subcluster-Specific Markers of B-Cell Subsets.
    Breast Cancer (Dove Med Press). 2026;18:580906.
    

    >> Share

    
    
24. WU W, He Y, Zhang C
    Emerging Targeted and Multimodal Therapeutic Strategies in Breast Cancer: A Comprehensive Review.
    Breast Cancer (Dove Med Press). 2026;18:575936.
    

    >> Share

    
    
25. CETIN TUNCEZ H, Adibelli ZH, Havvat N, Kocatepe Cavdar D, et al
    Radiological and Histopathological Predictors of Survival in Neuroendocrine Differentiated Breast Cancer: A Comparative Analysis with NS-IDC.
    Breast Cancer (Dove Med Press). 2026;18:569083.
    

    >> Share

    
    
26. ALSUHEBANY N, Alanazi A, Alzahrani MY, Alyousef S, et al
    Assessing Thrombotic Risk in Patients with HR+/HER2- Breast Cancer Receiving CDK4/6 Inhibitors: Insights from Real-World Data from the Middle East.
    Breast Cancer (Dove Med Press). 2026;18:554024.
    

    >> Share

    
    
27. CONG B, Martin TA, Cao X, Ruge FS, et al
    MLN51 (Metastatic Lymph Node Gene 51)/CASC3 (Cancer Susceptibility Candidate Gene 3), A Putative Tumour Suppressor in Breast Cancer, the Clinical and Therapeutic Connections.
    Breast Cancer (Dove Med Press). 2026;18:565199.
    

    >> Share

    
    
28. LIU Y, Zhang F, Guo C, Li Q, et al
    Prognostic Significance of the CRP-Albumin-Lymphocyte Index (CALLY) in Triple Negative Breast Cancer Patients: A Real-World Retrospective Study.
    Breast Cancer (Dove Med Press). 2026;18:582022.
    

    >> Share

    
    
29. CHEN H, Lu W, Zhou Y, Guo X, et al
    Recent Advances in Antibody-Drug Conjugates and Immunotherapy Combinations for Treatment of Triple-Negative Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:571054.
    

    >> Share

    
    

    
    Breast Cancer Res

30. WANG R, Liu S, Zhao Y, Su Y, et al
    TLScope: a deep learning framework for quantifying tertiary lymphoid structures from H&E images reveals prognostic heterogeneity across breast cancer subtypes.
    Breast Cancer Res. 2026 Mar 16. doi: 10.1186/s13058-026-02241.
    

    >> Share

    
    
31. MOSHINA N, Gjesvik J, Castells X, Larsen M, et al
    Breast cancer mortality among women who have attended BreastScreen Norway, 1996-2023.
    Breast Cancer Res. 2026 Mar 17. doi: 10.1186/s13058-026-02244.
    

    >> Share

    
    

    
    Breast Cancer Res Treat

32. SONG PN, Mansur A, Gallegos CA, Ghanate P, et al
    Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer.
    Breast Cancer Res Treat. 2026;216:25.
    

    >> Share

    
    
33. MANIKYA S, Vadhithala V, Kumar R, Nainwal P, et al
    Comment on: "Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors".
    Breast Cancer Res Treat. 2026;216:29.
    

    >> Share

    
    
34. JING F, Jiang L, Cao Y, Tian M, et al
    ESR1 polymorphisms were associated with aromatase inhibitors induced musculoskeletal symptoms in breast cancer patients.
    Breast Cancer Res Treat. 2026;216:28.
    

    >> Share

    
    
35. CASTELO BB, Brito LGO, Torresan RZ, Filho CC, et al
    Omission of axillary surgery in early breast cancer with negative lymph nodes: a systematic review and meta-analysis of randomized clinical trials.
    Breast Cancer Res Treat. 2026;216:30.
    

    >> Share

    
    
36. ANDRADE MO, Bonadio RC, Ipina A, Testa L, et al
    Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.
    Breast Cancer Res Treat. 2026;216:27.
    

    >> Share

    
    
37. MASUDA N, Yasojima H, Bando H, Yamanaka T, et al
    Long-term outcomes of eribulin?based neoadjuvant chemotherapy for triple?negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.
    Breast Cancer Res Treat. 2026;216:31.
    

    >> Share

    
    
38. DOYLE C, Lohmann AE, Iqbal N, Henning JW, et al
    Correction to: A Canadian real?world, multi?center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy +/- targeted therapy in HR + HER2?negat
    Breast Cancer Res Treat. 2026;216:32.
    

    >> Share

    
    
39. GUIRAO GARCIA ME, Marin Rodriguez P, Servet Perez de Lema CM, Blaya Boluda N, et al
    Unlocking the predictive value of post-neoadjuvant immune biomarkers in breast cancer: neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII).
    Breast Cancer Res Treat. 2026;216:26.
    

    >> Share

    
    

    
    Cancer Epidemiol Biomarkers Prev

40. JOHN EM, Koo J, Gomez SL, Keegan THM, et al
    Immigration and social factors, tumor stage, and risk of contralateral breast cancer in Asian American and Hispanic women.
    Cancer Epidemiol Biomarkers Prev. 2026.
    

    >> Share

    
    

    
    Cancer Lett

41. GAO YY, Lou KL, Lin LL, Li CX, et al
    A NIR-? fluorescent probe for real-time visualization and early assessment of responses to CDK4/6 inhibitors in breast cancer.
    Cancer Lett. 2026;646:218429.
    

    >> Share

    
    
42. FABRIZIO FP, Pegreffi F, Leonardi R, Mazza M, et al
    Can Macrophages Predict Response to Neoadjuvant Therapy in Lung Cancer? A Lesson from Breast Cancer.
    Cancer Lett. 2026 Mar 17:218438. doi: 10.1016/j.canlet.2026.218438.
    

    >> Share

    
    

    
    Cancer Res

43. XING Y, Tan Y, Hu B, Zhang H, et al
    PAK5-Mediated Suppression of beta-Hydroxybutyrate Production Promotes Breast Cancer Metastasis and Can Be Overcome with Ketogenic Diet.
    Cancer Res. 2026;86:1435-1450.
    

    >> Share

    
    

    
    Clin Breast Cancer

44. AKBIK M, Schultz S, Kanwar R, Nayudu K, et al
    Atypical Postradiation Vascular Proliferation: A Rare Dermatologic Sequela of Breast Cancer Therapy.
    Clin Breast Cancer. 2026;26:8-13.
    

    >> Share

    
    
45. LU Y, Yuan Q, Yu H, Li X, et al
    Impact of Post-Neoadjuvant Chemotherapy Biomarker Changes on Long-Term Oncological Outcomes in Non-pCR Breast Cancer.
    Clin Breast Cancer. 2026 Feb 24:S1526-8209(26)00021.
    

    >> Share

    
    
46. SEIN T
    Ultra-Low Dose Superparamagnetic Iron Oxide Nanoparticles for Sentinel Lymph Node Detection in Breast Cancer: A Literature Review.
    Clin Breast Cancer. 2026;26:14-16.
    

    >> Share

    
    
47. KURNIAWAN BUDI SUSILO Y, Yuliana D, Abdul Rahman S, Leong SL, et al
    A Deep Learning Framework for Automated Triage of Breast Cancer Biopsies in Malaysia: A Simulation Study to Reduce Resource Consumption and Diagnostic Turnaround Time.
    Clin Breast Cancer. 2026;26:44-50.
    

    >> Share

    
    

    
    Clin Cancer Res

48. CARLETON N, Chang AC, Chen F, Puhalla SL, et al
    Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies.
    Clin Cancer Res. 2026 Mar 19:OF1-OF11. doi: 10.1158/1078-0432.CCR-25-4079.
    

    >> Share

    
    
49. SALGADO R, Kok M
    Immunity, age, and luminal breast cancer: understanding the Holy Trinity.
    Clin Cancer Res. 2026 Mar 19. doi: 10.1158/1078-0432.CCR-25-4035.
    

    >> Share

    
    

    
    Eur J Cancer

50. WANG X, Chen L, Sun J, Khalighi S, et al
    MuTriM: A multiscale deep learning model integrating longitudinal radiomics and pathomic features for predicting recurrence and adjuvant radiation benefit in breast cancer.
    Eur J Cancer. 2026;238:116679.
    

    >> Share

    
    

    
    Eur J Surg Oncol

51. TIMOTEO R, Laborde A, Forghani Y, Santinha J, et al
    Automatic and high-resolution surface scan system for breast cancer treatment: clinical accuracy and usability assessment.
    Eur J Surg Oncol. 2026;52:111507.
    

    >> Share

    
    
52. KLIMBERG VS
    Breast cancer: A success story for women.
    Eur J Surg Oncol. 2026;52:111491.
    

    >> Share

    
    

    
    Eur Radiol

53. OZTURK M, Gurun E
    Letter to the Editor: Shear-wave dispersion imaging in breast cancer: methodological considerations and future perspectives.
    Eur Radiol. 2026 Mar 16. doi: 10.1007/s00330-026-12470.
    

    >> Share

    
    
54. WOO E, Lee JY, Seo BK
    Reply to the Letter to the Editor: Shear-wave dispersion imaging in breast cancer: methodological considerations and future perspectives.
    Eur Radiol. 2026 Mar 16. doi: 10.1007/s00330-026-12471.
    

    >> Share

    
    

    
    Int J Cancer

55. MARSCHNER P, Ringwald K, Thill M, Zahn MO, et al
    Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.
    Int J Cancer. 2026 Mar 18. doi: 10.1002/ijc.70433.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

56. ZHENG L, Yang M, Luo C, Lv X, et al
    Radiation-Induced Acute Cardiac Injury in Patients With Left-Sided Breast Cancer: A Cardiac Magnetic Resonance Study on the Dose-Response Relation.
    Int J Radiat Oncol Biol Phys. 2026 Mar 16:S0360-3016(26)00400.
    

    >> Share

    
    
57. CHANG JS, Kim MH, Lee BM, Sohn J, et al
    Patterns of progression after first-line systemic therapy in metastatic breast cancer and the potential of ctDNA to guide metastasis-directed therapy: implications for breast oligometastases management.
    Int J Radiat Oncol Biol Phys. 2026 Mar 18:S0360-3016(26)00497.
    

    >> Share

    
    

    
    J Clin Oncol

58. SCHNEIDER BP, Stover DG
    From Prognosis to Action: Circulating Tumor DNA and the Next Phase of Risk Stratification in Triple-Negative Breast Cancer.
    J Clin Oncol. 2026 Mar 18:JCO2600103. doi: 10.1200/JCO-26-00103.
    

    >> Share

    
    

    
    J Natl Cancer Inst

59. YADAV S, Reid S, Yilma B, Fragkogianni S, et al
    Landscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genes.
    J Natl Cancer Inst. 2026 Mar 14:djag070. doi: 10.1093.
    

    >> Share

    
    

    
    J Surg Oncol

60. ALTUNDAG K
    Discordance Between Breast and Nodal Pathologic Response in Triple-Negative Breast Cancer: Methodological Considerations and Contemporary Implications.
    J Surg Oncol. 2026 Mar 16. doi: 10.1002/jso.70241.
    

    >> Share

    
    

    
    Lancet Oncol

61. SHAMAI G, Cohen S, Binenbaum Y, Sabo E, et al
    Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study.
    Lancet Oncol. 2026 Mar 11:S1470-2045(25)00727.
    

    >> Share

    
    

    
    NPJ Breast Cancer

62. ZHOU C, Crusher JT, Friesen K, Twigger SA, et al
    HIF-1-regulated TPM3 links hypoxia to motility and invasion beyond the hypoxic fraction in triple-negative breast cancer.
    NPJ Breast Cancer. 2026 Mar 14. doi: 10.1038/s41523-026-00927.
    

    >> Share

    
    
63. AOUAD P, Halabi K, Hayar B, Sflomos G, et al
    Preclinical models of breast cancer metastasis: strengths, limitations, and clinical relevance.
    NPJ Breast Cancer. 2026 Mar 14. doi: 10.1038/s41523-026-00928.
    

    >> Share

    
    
64. SU A, Hong EC, Moxon N, Mellinger SL, et al
    Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer.
    NPJ Breast Cancer. 2026 Mar 17. doi: 10.1038/s41523-026-00925.
    

    >> Share

    
    
65. BLEACH R, Bozkurt E, Xin J, Sheehan KM, et al
    Androgen receptor localisation and protein interactions provide insight into steroid mediated metabolic shifts in endocrine resistant breast cancer.
    NPJ Breast Cancer. 2026 Mar 17. doi: 10.1038/s41523-026-00924.
    

    >> Share

    
    
66. ULLAH E, Abdel-Razeq H, Bentebbal S, Shaar A, et al
    Comprehensive genomic analysis of non-BRCA familial breast cancer in an Arab population.
    NPJ Breast Cancer. 2026 Mar 19. doi: 10.1038/s41523-026-00926.
    

    >> Share

    
    
67. REID S, Venton L, Whisenant JG, Weidner AE, et al
    Identification of racial disparities across MammaPrint and BluePrint subtypes in HR + HER2- breast cancer.
    NPJ Breast Cancer. 2026 Mar 19. doi: 10.1038/s41523-026-00932.
    

    >> Share

    
    
68. AVILA L, Seoane S, Rodriguez-Gonzalez S, Gois M, et al
    POU1F1 induces cancer stem cell-like traits in breast cancer cells by IL-6/JAK2/STAT3 activation and enrichment of ALDH.
    NPJ Breast Cancer. 2026 Mar 19. doi: 10.1038/s41523-026-00929.
    

    >> Share

    
    
69. KHOR CC, Ong WS, Lim EH, Chatelut E, et al
    A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence.
    NPJ Breast Cancer. 2026 Mar 20. doi: 10.1038/s41523-026-00931.
    

    >> Share

    
    

    
    Oncol Rep

70. LIU R, Lin Z, Li Y, Ci Y, et al
    Mechanistic insights into the roles of astragalosides and Astragalus polysaccharides in gynecological and breast cancers (Review).
    Oncol Rep. 2026;55:97.
    

    >> Share

    
    

    
    PLoS One

71. ALIPOUR S, Jafari K, Saberi A, Motamedi M, et al
    What is the significance of a new breast mass in women aged 40 or above? A cross-sectional study.
    PLoS One. 2026;21:e0341732.
    

    >> Share

    
    
72. RAFI MSH, Millat MS, Barek MA, Dewan SMR, et al
    Association of NUDT17 rs9286836 and rs2004659 variants with breast cancer risk in Bangladeshi Women.
    PLoS One. 2026;21:e0344584.
    

    >> Share

    
    
73. SIAM MBH, Khan MR, Elahe MF, Arman MS, et al
    Effects of similarity networks in graph-based multi-omics classification.
    PLoS One. 2026;21:e0344754.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

74. FASSL A, Palacios Espinoza M, Butter D, Kolodziejczyk A, et al
    Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6.
    Proc Natl Acad Sci U S A. 2026;123:e2522872123.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share